Kalaris Therapeutics Inc. Company Profile
NASDAQ: KLRSHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
Market open · Delayed 15 min · as of Oct 8, 4:00 PM ET
Kalaris Therapeutics at a glance
Kalaris Therapeutics Inc. (NASDAQ: KLRS) is a Biotechnology: Biological Products (No Diagnostic Substances) company in the Health Care sector headquartered in Berkeley Heights, NJ. Kalaris Therapeutics is led by Mr. Andrew Oxtoby and employs about 20 people. The company's shares have traded publicly since 2020.
At a market capitalization of $59.5 million, it is considered a small-cap company. Its SEC Central Index Key (CIK) is 0001754068, which identifies the company's filings on EDGAR.
Summary generated from market data by MetaCap's automated system. Methodology
What does Kalaris Therapeutics do?
Kalaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for prevalent retinal diseases. It develops TH103, a clinical-stage anti-vascular endothelial growth factor (VEGF) drug for the treatment of neovascular age-related macular degeneration (nAMD), which is in Phase 1b/2, as well as for the treatment of other exudative and neovascular retinal diseases. Kalaris Therapeutics, Inc. was formerly known as Theia Therapeutics, Inc. and changed its name to Kalaris Therapeutics, Inc. in May 2024. The company was founded in 2019 and is headquartered in Berkeley Heights, New Jersey.
Business description based on the company's public filings.
Company information
- Legal name
- Kalaris Therapeutics Inc.
- Ticker
- NASDAQ: KLRS
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- CEO
- Mr. Andrew Oxtoby
- Employees
- 20
- Headquarters
- 400 Connell Drive, Berkeley Heights, NJ, United States
- Phone
- 650 249 2727
- Website
- kalaristx.com
- IPO year
- 2020
- Market cap
- $59.51M
- SEC CIK
- 0001754068
- Latest annual report
- 10-K · Mar 17, 2026
Companies similar to Kalaris Therapeutics
| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| ELOXEloxx Pharmaceuticals Inc. | 15.02 | -1.05% | $60.63M | vs KLRS |
| LONALeonaBio Inc. | 6.10 | +6.10% | $57.47M | vs KLRS |
| INKTMiNK Therapeutics Inc. | 11.00 | 0.00% | $56.13M | vs KLRS |
| INMBINmune Bio Inc. | 1.87 | +2.19% | $51.90M | vs KLRS |
| BKHABlack Hawk Acquisition Corporation Class A | 12.33 | 0.00% | $51.21M | vs KLRS |
| CRBUCaribou Biosciences Inc. | 0.4641 | -3.56% | $49.76M | vs KLRS |
| CSBRChampions Oncology Inc. | 4.98 | 0.00% | $69.31M | vs KLRS |
| EXOZeXoZymes Inc. | 5.33 | 0.00% | $49.59M | vs KLRS |